MOF-based STING agonist delivery systems have shown considerable promise, with multiple studies indicating that MOFs can effectively deliver STING agonists, such as cGAMP and c-di-GMP, to tumor cells, thereby activating the cGAS-STING pathway and inducing type I interferon responses along with anti-tumor immunity (92, 96, 97). The gene discussed is CGAS; the disease is neoplasm.